Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
June 10 2014 - 4:00PM
Marketwired
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series
E Convertible Preferred Stock
TUSTIN, CA--(Marketwired - Jun 10, 2014) - Peregrine
Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today
announced that its Board of Directors has declared a quarterly cash
dividend payment on the Company's 10.50% Series E Convertible
Preferred Stock (the "Series E Preferred Stock").
The quarterly dividend on the Series E Preferred Stock is
payable on July 1, 2014 to holders of record at the close of
business on June 20, 2014.
The quarterly dividend payment on the Series E Preferred Stock
will be $0.65625 per share, which is equivalent to an annualized
10.50% per share, based on the $25.00 per share stated liquidation
preference, accruing from April 1, 2014 through June 30, 2014. The
Series E Preferred Stock is listed on the NASDAQ Capital Market and
trades under the ticker symbol "PPHMP".
About Peregrine Pharmaceuticals, Inc. Peregrine Pharmaceuticals,
Inc. is a biopharmaceutical company with a pipeline of novel drug
candidates in clinical trials for the treatment and diagnosis of
cancer. The company is pursuing multiple clinical programs in
cancer with its lead immunotherapy candidate bavituximab while
seeking a partner to further advance its novel brain cancer agent
Cotara®. Peregrine also has in-house cGMP manufacturing
capabilities through its wholly-owned subsidiary Avid Bioservices,
Inc. (www.avidbio.com), which provides development and
biomanufacturing services for both Peregrine and third-party
customers. Additional information about Peregrine can be found at
www.peregrineinc.com.
Contact: Christopher Keenan or Jay Carlson Peregrine
Pharmaceuticals (800) 987-8256 info@peregrineinc.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Sep 2023 to Sep 2024